ArticleScientific reports2026
Circulating ACE2 levels and ACE I/D polymorphism in severe aortic stenosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The renin-angiotensin system (RAS) contributes to the fibro-calcific remodeling characteristic of aortic stenosis (AS). Although increased circulating ACE2 enzymatic activity has been reported in severe AS, data on circulating ACE2 protein concentration, ACE levels, and their relationship with ACE genetic variation remain limited. In this cross-sectional case-control study, 80 participants (40 severe AS, 40 matched controls) underwent measurement of circulating ACE and ACE2 concentrations by ELISA and genotyping for the ACE insertion/deletion (I/D) polymorphism (rs4340). Multivariable logistic regression assessed the independent association between ACE2 and severe AS after adjustment for age, serum creatinine, ACEi/ARB therapy, and genotype. Firth penalized regression was performed as sensitivity analysis. Circulating ACE2 concentrations were higher in severe AS compared with controls (median 1.9 vs. 0.8 ng/mL, p = 0.005), whereas ACE levels were similar between groups. ACE2 remained independently associated with severe AS (odds ratio per doubling 1.48, 95% CI 1.05-2.08; p = 0.025), with consistent estimates in penalized models. ACE I/D genotype distribution differed between groups (p = 0.012), with the II genotype independently associated with severe AS compared with ID. Neither circulating ACE2 nor ACE I/D genotype correlated with echocardiographic indices of stenosis severity or CT-derived valvular calcification. Severe AS was associated with higher circulating ACE2 concentrations despite comparable ACE levels and a differential distribution of the ACE I/D polymorphism, consistent with altered systemic RAS balance in advanced valvular disease. These findings are hypothesis-generating and require validation in larger prospective cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.